$MTSR $PFE$NVO
Pfizer beats out Novo in bidding war for obesity-drug startup Metsera www.statnews.com/2025/11/07/p... via @statnews.com
Pfizer beats out Novo in bidding war for obesity-drug startup Metsera www.statnews.com/2025/11/07/p... via @statnews.com
Pfizer beats out Novo in bidding war for obesity-drug startup Metsera
Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera
www.statnews.com
November 8, 2025 at 3:39 PM
$MTSR $PFE$NVO
Pfizer beats out Novo in bidding war for obesity-drug startup Metsera www.statnews.com/2025/11/07/p... via @statnews.com
Pfizer beats out Novo in bidding war for obesity-drug startup Metsera www.statnews.com/2025/11/07/p... via @statnews.com
$ZTS
Zoetis Announces Third Quarter 2025 Results - www.businesswire.com/news/home/20...
Zoetis Announces Third Quarter 2025 Results - www.businesswire.com/news/home/20...
www.businesswire.com
November 4, 2025 at 1:41 PM
$ZTS
Zoetis Announces Third Quarter 2025 Results - www.businesswire.com/news/home/20...
Zoetis Announces Third Quarter 2025 Results - www.businesswire.com/news/home/20...
$RARE
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups www.globenewswire.com/news-release...
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups www.globenewswire.com/news-release...
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
NOVATO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patient has been dosed in...
www.globenewswire.com
October 30, 2025 at 1:40 PM
$RARE
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups www.globenewswire.com/news-release...
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups www.globenewswire.com/news-release...
$IBM
IBM releases small open-source Granite 4 models for mobile devices and browsers siliconangle.com/2025/10/29/i...
IBM releases small open-source Granite 4 models for mobile devices and browsers siliconangle.com/2025/10/29/i...
IBM releases small open-source Granite 4 models for mobile devices and browsers - SiliconANGLE
IBM releases small open-source Granite 4 models for mobile devices and browsers - SiliconANGLE
siliconangle.com
October 29, 2025 at 4:32 PM
$IBM
IBM releases small open-source Granite 4 models for mobile devices and browsers siliconangle.com/2025/10/29/i...
IBM releases small open-source Granite 4 models for mobile devices and browsers siliconangle.com/2025/10/29/i...
$CHKP $CVLT
Cybersecurity stocks diverge as Commvault disappoints and Check Point surges on AI-driven results siliconangle.com/2025/10/28/c...
Cybersecurity stocks diverge as Commvault disappoints and Check Point surges on AI-driven results siliconangle.com/2025/10/28/c...
Cybersecurity stocks diverge as Commvault disappoints and Check Point surges on AI-driven results - SiliconANGLE
Cybersecurity stocks diverge as Commvault disappoints and Check Point surges on AI-driven results - SiliconANGLE
siliconangle.com
October 28, 2025 at 11:52 PM
$CHKP $CVLT
Cybersecurity stocks diverge as Commvault disappoints and Check Point surges on AI-driven results siliconangle.com/2025/10/28/c...
Cybersecurity stocks diverge as Commvault disappoints and Check Point surges on AI-driven results siliconangle.com/2025/10/28/c...
$BBIO
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th www.globenewswire.com/news-release...
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th www.globenewswire.com/news-release...
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical...
www.globenewswire.com
October 28, 2025 at 8:49 PM
$BBIO
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th www.globenewswire.com/news-release...
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th www.globenewswire.com/news-release...
$WM
WM Announces Third Quarter 2025 Earnings - www.businesswire.com/news/home/20...
WM Announces Third Quarter 2025 Earnings - www.businesswire.com/news/home/20...
www.businesswire.com
October 27, 2025 at 9:19 PM
$WM
WM Announces Third Quarter 2025 Earnings - www.businesswire.com/news/home/20...
WM Announces Third Quarter 2025 Earnings - www.businesswire.com/news/home/20...
$AMKR
Amkor Technology Reports Financial Results for the Third Quarter 2025
- Net sales $1.99 billion
- Gross profit $284 million, operating income $159 million
- Net income $127 million, earnings per diluted share $0.51
million
www.businesswire.com/news/home/20...
Amkor Technology Reports Financial Results for the Third Quarter 2025
- Net sales $1.99 billion
- Gross profit $284 million, operating income $159 million
- Net income $127 million, earnings per diluted share $0.51
million
www.businesswire.com/news/home/20...
www.businesswire.com
October 27, 2025 at 9:15 PM
$AMKR
Amkor Technology Reports Financial Results for the Third Quarter 2025
- Net sales $1.99 billion
- Gross profit $284 million, operating income $159 million
- Net income $127 million, earnings per diluted share $0.51
million
www.businesswire.com/news/home/20...
Amkor Technology Reports Financial Results for the Third Quarter 2025
- Net sales $1.99 billion
- Gross profit $284 million, operating income $159 million
- Net income $127 million, earnings per diluted share $0.51
million
www.businesswire.com/news/home/20...
$CLS
Celestica Announces Third Quarter 2025 Financial Results and Will Hold 2025 Investor and Analyst Day
- Revenue was $3.19 billion, increased 28% compared to $2.50 billion for third quarter of 2024 (Q3 2024)
www.globenewswire.com/news-release...
Celestica Announces Third Quarter 2025 Financial Results and Will Hold 2025 Investor and Analyst Day
- Revenue was $3.19 billion, increased 28% compared to $2.50 billion for third quarter of 2024 (Q3 2024)
www.globenewswire.com/news-release...
Celestica Announces Third Quarter 2025 Financial Results and Will Hold 2025 Investor and Analyst Day
Q3 2025 revenue and adjusted EPS* above the high end of our guidance ranges; Raising 2025 annual outlook...
www.globenewswire.com
October 27, 2025 at 9:09 PM
$CLS
Celestica Announces Third Quarter 2025 Financial Results and Will Hold 2025 Investor and Analyst Day
- Revenue was $3.19 billion, increased 28% compared to $2.50 billion for third quarter of 2024 (Q3 2024)
www.globenewswire.com/news-release...
Celestica Announces Third Quarter 2025 Financial Results and Will Hold 2025 Investor and Analyst Day
- Revenue was $3.19 billion, increased 28% compared to $2.50 billion for third quarter of 2024 (Q3 2024)
www.globenewswire.com/news-release...
$NXPI
NXP Semiconductors Reports Third Quarter 2025 Results
- Revenue was $3.17 billion, down 2 percent year-on-year;
- GAAP gross margin was 56.3 percent, GAAP operating margin was 28.1 percent and GAAP diluted Net Income per Share was $2.48
NXP Semiconductors Reports Third Quarter 2025 Results
- Revenue was $3.17 billion, down 2 percent year-on-year;
- GAAP gross margin was 56.3 percent, GAAP operating margin was 28.1 percent and GAAP diluted Net Income per Share was $2.48
NXP Semiconductors Reports Third Quarter 2025 Results
EINDHOVEN, The Netherlands, Oct. 27, 2025 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ: NXPI) today reported financial results for the third...
www.globenewswire.com
October 27, 2025 at 9:06 PM
$NXPI
NXP Semiconductors Reports Third Quarter 2025 Results
- Revenue was $3.17 billion, down 2 percent year-on-year;
- GAAP gross margin was 56.3 percent, GAAP operating margin was 28.1 percent and GAAP diluted Net Income per Share was $2.48
NXP Semiconductors Reports Third Quarter 2025 Results
- Revenue was $3.17 billion, down 2 percent year-on-year;
- GAAP gross margin was 56.3 percent, GAAP operating margin was 28.1 percent and GAAP diluted Net Income per Share was $2.48
$NTLA
For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat www.statnews.com/2025/10/27/i... via @statnews.com
For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat www.statnews.com/2025/10/27/i... via @statnews.com
For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat
Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, potentially fatal, liver toxicity.
www.statnews.com
October 27, 2025 at 7:48 PM
$NTLA
For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat www.statnews.com/2025/10/27/i... via @statnews.com
For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat www.statnews.com/2025/10/27/i... via @statnews.com
$NTLA
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) www.globenewswire.com/news-release...
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) www.globenewswire.com/news-release...
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Conference call today at 8:30 a.m. ET...
www.globenewswire.com
October 27, 2025 at 2:07 PM
$NTLA
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) www.globenewswire.com/news-release...
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) www.globenewswire.com/news-release...
$GH
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
- Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test
www.businesswire.com/news/home/20...
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
- Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test
www.businesswire.com/news/home/20...
www.businesswire.com
October 27, 2025 at 1:35 AM
$GH
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
- Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test
www.businesswire.com/news/home/20...
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
- Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test
www.businesswire.com/news/home/20...
$LLY $INCY
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
www.clinicaltrialsarena.com/news/lilly-a... via @TrialsArena
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
www.clinicaltrialsarena.com/news/lilly-a... via @TrialsArena
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
Lilly and Inctye will be seeking a label update for the JAK inhibitor for its use in paediatric patients with alopecia areata.
www.clinicaltrialsarena.com
October 26, 2025 at 9:23 PM
$LLY $INCY
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
www.clinicaltrialsarena.com/news/lilly-a... via @TrialsArena
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
www.clinicaltrialsarena.com/news/lilly-a... via @TrialsArena
$GH
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 - www.businesswire.com/news/home/20...
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 - www.businesswire.com/news/home/20...
www.businesswire.com
October 26, 2025 at 8:27 PM
$GH
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 - www.businesswire.com/news/home/20...
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 - www.businesswire.com/news/home/20...
$CSTL
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus www.globenewswire.com/news-release...
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus www.globenewswire.com/news-release...
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’...
Castle announced new data on its TissueCypher® Barrett’s Esophagus test being presented at ACG 2025....
www.globenewswire.com
October 26, 2025 at 8:25 PM
$CSTL
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus www.globenewswire.com/news-release...
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus www.globenewswire.com/news-release...
$FATE
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy www.globenewswire.com/news-release...
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy www.globenewswire.com/news-release...
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shel...
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated...
www.globenewswire.com
October 26, 2025 at 8:23 PM
$FATE
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy www.globenewswire.com/news-release...
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy www.globenewswire.com/news-release...
$UMAC
Trump Jr.-backed Drone Firm Lands Pentagon’s Biggest Contract
-Trump Jr. holds $4 million stake in company
www.livemint.com/news/us-news...
Trump Jr.-backed Drone Firm Lands Pentagon’s Biggest Contract
-Trump Jr. holds $4 million stake in company
www.livemint.com/news/us-news...
Trump Jr-backed drone firm lands Pentagon’s biggest contract, set to supply thousands of drone parts | Today News
Trump Jr holds a $4 million stake in the company. When asked if Donald Trump Jr helped the company with the deal, Unusual Machines Chief Executive Allan Evans said that he did not
www.livemint.com
October 26, 2025 at 8:18 PM
$UMAC
Trump Jr.-backed Drone Firm Lands Pentagon’s Biggest Contract
-Trump Jr. holds $4 million stake in company
www.livemint.com/news/us-news...
Trump Jr.-backed Drone Firm Lands Pentagon’s Biggest Contract
-Trump Jr. holds $4 million stake in company
www.livemint.com/news/us-news...
$NVS $RNA
Novartis to Acquire Avidity Biosciences for about $12 billion
- $72 per share
www.reuters.com/business/hea...
Novartis to Acquire Avidity Biosciences for about $12 billion
- $72 per share
www.reuters.com/business/hea...
Novartis to acquire Avidity Biosciences for about $12 billion
Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare muscle disorders.
www.reuters.com
October 26, 2025 at 7:57 PM
$NVS $RNA
Novartis to Acquire Avidity Biosciences for about $12 billion
- $72 per share
www.reuters.com/business/hea...
Novartis to Acquire Avidity Biosciences for about $12 billion
- $72 per share
www.reuters.com/business/hea...
apnews.com/live/stock-m... updates: - Stocks sink globally as Trump pushes ahead with trade war -
Live updates: Stocks sink globally as Trump pushes ahead with trade war
U.S. stocks are falling in a manic Monday after President Donald Trump doubled down on his tariffs, despite seeing how much financial markets would love to see him do the opposite. The S&P 500 was dow...
apnews.com
April 7, 2025 at 7:00 PM
apnews.com/live/stock-m... updates: - Stocks sink globally as Trump pushes ahead with trade war -
Notable 52 Week Highs
Continued
$IMVT
$INGM
$IOVA
$JAMF
$KROS
$KSS
$KURA
$KYTX
$LEG
$LEN
$LYB
$MOS
$MRTN
$NABL
$NAT
$NAVI
$NTLA
$NTST
$OBIO
$OLED
$ORKA
$OSUR
$PACS
$PMT
$RKT
$ROCK
$RXST
$RYN
$SBLK
$SITC
$SLRN
$SNDX
$SSL
$ST
$STAA
$STNE
$STZ
$SWBI
$TMDX
$TU
$TX
$TXT
$UGP
$VIV
$VTEX
$WHO
$ZEUS
$ZIP
Continued
$IMVT
$INGM
$IOVA
$JAMF
$KROS
$KSS
$KURA
$KYTX
$LEG
$LEN
$LYB
$MOS
$MRTN
$NABL
$NAT
$NAVI
$NTLA
$NTST
$OBIO
$OLED
$ORKA
$OSUR
$PACS
$PMT
$RKT
$ROCK
$RXST
$RYN
$SBLK
$SITC
$SLRN
$SNDX
$SSL
$ST
$STAA
$STNE
$STZ
$SWBI
$TMDX
$TU
$TX
$TXT
$UGP
$VIV
$VTEX
$WHO
$ZEUS
$ZIP
December 31, 2024 at 1:07 AM
Notable 52 Week Highs
Continued
$IMVT
$INGM
$IOVA
$JAMF
$KROS
$KSS
$KURA
$KYTX
$LEG
$LEN
$LYB
$MOS
$MRTN
$NABL
$NAT
$NAVI
$NTLA
$NTST
$OBIO
$OLED
$ORKA
$OSUR
$PACS
$PMT
$RKT
$ROCK
$RXST
$RYN
$SBLK
$SITC
$SLRN
$SNDX
$SSL
$ST
$STAA
$STNE
$STZ
$SWBI
$TMDX
$TU
$TX
$TXT
$UGP
$VIV
$VTEX
$WHO
$ZEUS
$ZIP
Continued
$IMVT
$INGM
$IOVA
$JAMF
$KROS
$KSS
$KURA
$KYTX
$LEG
$LEN
$LYB
$MOS
$MRTN
$NABL
$NAT
$NAVI
$NTLA
$NTST
$OBIO
$OLED
$ORKA
$OSUR
$PACS
$PMT
$RKT
$ROCK
$RXST
$RYN
$SBLK
$SITC
$SLRN
$SNDX
$SSL
$ST
$STAA
$STNE
$STZ
$SWBI
$TMDX
$TU
$TX
$TXT
$UGP
$VIV
$VTEX
$WHO
$ZEUS
$ZIP
Today’s Notable 52 Week Lows
$ACHV
$ACRE
$ADVM
$AEO
$ALMS
$AMBP
$ANAB
$AOS
$ARCO
$ASGN
$BAK
$BAX
$BC
$BCE
$BDTX
$BF.A
$BF.B
$BG
$BHP
$BYON
$CCCC
$CCI
$CGC
$CLF
$CMPS
$COLD
$COLL
$COTY
$CRSP
$DBRG
$FMC
$GGB
$GMRE
$GOTU
$GPCR
$GPRE
$GSBD
$GSM
$HBIO
$HOG
$HUN
$ICG
$IDYA
$IEP
$IGMS
$IGT
Continued
$ACHV
$ACRE
$ADVM
$AEO
$ALMS
$AMBP
$ANAB
$AOS
$ARCO
$ASGN
$BAK
$BAX
$BC
$BCE
$BDTX
$BF.A
$BF.B
$BG
$BHP
$BYON
$CCCC
$CCI
$CGC
$CLF
$CMPS
$COLD
$COLL
$COTY
$CRSP
$DBRG
$FMC
$GGB
$GMRE
$GOTU
$GPCR
$GPRE
$GSBD
$GSM
$HBIO
$HOG
$HUN
$ICG
$IDYA
$IEP
$IGMS
$IGT
Continued
December 31, 2024 at 12:58 AM
Today’s Notable 52 Week Lows
$ACHV
$ACRE
$ADVM
$AEO
$ALMS
$AMBP
$ANAB
$AOS
$ARCO
$ASGN
$BAK
$BAX
$BC
$BCE
$BDTX
$BF.A
$BF.B
$BG
$BHP
$BYON
$CCCC
$CCI
$CGC
$CLF
$CMPS
$COLD
$COLL
$COTY
$CRSP
$DBRG
$FMC
$GGB
$GMRE
$GOTU
$GPCR
$GPRE
$GSBD
$GSM
$HBIO
$HOG
$HUN
$ICG
$IDYA
$IEP
$IGMS
$IGT
Continued
$ACHV
$ACRE
$ADVM
$AEO
$ALMS
$AMBP
$ANAB
$AOS
$ARCO
$ASGN
$BAK
$BAX
$BC
$BCE
$BDTX
$BF.A
$BF.B
$BG
$BHP
$BYON
$CCCC
$CCI
$CGC
$CLF
$CMPS
$COLD
$COLL
$COTY
$CRSP
$DBRG
$FMC
$GGB
$GMRE
$GOTU
$GPCR
$GPRE
$GSBD
$GSM
$HBIO
$HOG
$HUN
$ICG
$IDYA
$IEP
$IGMS
$IGT
Continued
Today’s Notable 52 Week Highs
$ALLT
$AMPG
$ARTW
$ATHE
$BBAI
$BCSF
$BLBX
$CAE
$CDTX
$CDZI
$CMRX
$COCP
$CSBR
$CTM
$EXE
$GRND
$GRRR
$HSAI
$HSBC
$JBLU
$MESO
$MIND
$MVST
$ONDS
$PDYN
$RDW
$REAL
$SES
$TARS
$TBRG
$VNET
$VRNA
$WIMI
$ALLT
$AMPG
$ARTW
$ATHE
$BBAI
$BCSF
$BLBX
$CAE
$CDTX
$CDZI
$CMRX
$COCP
$CSBR
$CTM
$EXE
$GRND
$GRRR
$HSAI
$HSBC
$JBLU
$MESO
$MIND
$MVST
$ONDS
$PDYN
$RDW
$REAL
$SES
$TARS
$TBRG
$VNET
$VRNA
$WIMI
December 31, 2024 at 12:47 AM
Today’s Notable 52 Week Highs
$ALLT
$AMPG
$ARTW
$ATHE
$BBAI
$BCSF
$BLBX
$CAE
$CDTX
$CDZI
$CMRX
$COCP
$CSBR
$CTM
$EXE
$GRND
$GRRR
$HSAI
$HSBC
$JBLU
$MESO
$MIND
$MVST
$ONDS
$PDYN
$RDW
$REAL
$SES
$TARS
$TBRG
$VNET
$VRNA
$WIMI
$ALLT
$AMPG
$ARTW
$ATHE
$BBAI
$BCSF
$BLBX
$CAE
$CDTX
$CDZI
$CMRX
$COCP
$CSBR
$CTM
$EXE
$GRND
$GRRR
$HSAI
$HSBC
$JBLU
$MESO
$MIND
$MVST
$ONDS
$PDYN
$RDW
$REAL
$SES
$TARS
$TBRG
$VNET
$VRNA
$WIMI
$AXSM
- Axsome Flashes A Bearish Signal on Mixed Results in Alzheimer’s Agitation
www.investors.com/news/technol...
- Axsome Flashes A Bearish Signal on Mixed Results in Alzheimer’s Agitation
www.investors.com/news/technol...
Biotech Flashes A Bearish Signal On Mixed Alzheimer's Studies
Shares of dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.
www.investors.com
December 31, 2024 at 12:39 AM
$AXSM
- Axsome Flashes A Bearish Signal on Mixed Results in Alzheimer’s Agitation
www.investors.com/news/technol...
- Axsome Flashes A Bearish Signal on Mixed Results in Alzheimer’s Agitation
www.investors.com/news/technol...